LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ranibizumab" as a keyword



Photo by srosinger3997 from unsplash

Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015.

Sign Up to like & get
recommendations! Published in 2019 at "JAMA ophthalmology"

DOI: 10.1001/jamaophthalmol.2019.1971

Abstract: Importance The frequency of anti-vascular endothelial growth factor (VEGF) injections has grown exponentially with the introduction of bevacizumab, ranibizumab, and most recently aflibercept. The cost associated with these medications has garnered significant national attention, warranting… read more here.

Keywords: part beneficiaries; bevacizumab; part; 2012 2015 ... See more keywords
Photo by lgnwvr from unsplash

Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: an Analysis of the FDA Adverse Event Reporting System database (FAERS).

Sign Up to like & get
recommendations! Published in 2023 at "Journal of clinical pharmacology"

DOI: 10.1002/jcph.2244

Abstract: The cardiovascular and cerebrovascular safety of ranibizumab, bevacizumab, and aflibercept for ocular diseases is unclear. This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for… read more here.

Keywords: ranibizumab bevacizumab; cardiovascular cerebrovascular; bevacizumab aflibercept; bevacizumab ... See more keywords
Photo by goian from unsplash

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Sign Up to like & get
recommendations! Published in 2017 at "Graefe's Archive for Clinical and Experimental Ophthalmology"

DOI: 10.1007/s00417-017-3685-y

Abstract: PurposeTo evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) in a real-world setting.MethodsA descriptive, observational, multicenter study in a retrospective and prospective cohort… read more here.

Keywords: choroidal neovascularization; ranibizumab; year; safety ... See more keywords
Photo by schluditsch from unsplash

Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration

Sign Up to like & get
recommendations! Published in 2018 at "International Ophthalmology"

DOI: 10.1007/s10792-018-0833-2

Abstract: PurposeTo compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a… read more here.

Keywords: aflibercept treatment; treatment vascularized; ranibizumab; vascularized pigment ... See more keywords
Photo from wikipedia

A Review of Ranibizumab for the Treatment of Diabetic Retinopathy

Sign Up to like & get
recommendations! Published in 2017 at "Ophthalmology and Therapy"

DOI: 10.1007/s40123-017-0083-9

Abstract: IntroductionLaser photocoagulation has been the standard treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) for several decades. The discovery of vascular endothelial growth factor (VEGF) and the subsequent determination of its critical… read more here.

Keywords: diabetic retinopathy; ranibizumab; treatment diabetic; treatment ... See more keywords
Photo by schluditsch from unsplash

Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".

Sign Up to like & get
recommendations! Published in 2019 at "Ophthalmology"

DOI: 10.1016/j.ophtha.2019.08.010

Abstract: PURPOSE To evaluate panretinal photocoagulation (PRP) treatment and re-treatment patterns in patients with diabetic retinopathy (DR) and diabetic macular edema (DME). DESIGN Post hoc analysis of the phase 3 RIDE (clinicaltrials.gov identifier, NCT00473382) and RISE… read more here.

Keywords: ranibizumab; treatment; prior prp; treated patients ... See more keywords
Photo by schluditsch from unsplash

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

Sign Up to like & get
recommendations! Published in 2019 at "The Lancet"

DOI: 10.1016/s0140-6736(19)31344-3

Abstract: BACKGROUND Despite increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the appropriate drug and dose, the need for retreatment,… read more here.

Keywords: treatment; trial; ranibizumab; laser therapy ... See more keywords
Photo from wikipedia

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set

Sign Up to like & get
recommendations! Published in 2017 at "Eye"

DOI: 10.1038/eye.2017.143

Abstract: PurposeTo examine 12-month real-world visual acuity outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes, including those with pigment epithelial detachment (PED), receiving ranibizumab or aflibercept.Patients and methodsElectronic medical records were used to… read more here.

Keywords: real world; aflibercept treatment; ranibizumab; ranibizumab aflibercept ... See more keywords
Photo by schluditsch from unsplash

The impact of LEAVO study in Greece

Sign Up to like & get
recommendations! Published in 2019 at "Eye"

DOI: 10.1038/s41433-019-0714-6

Abstract: Macular edema is the leading cause of visual impairment in patients with central retinal vein occlusion (CRVO) [1]. Currently, intravitreal anti-vascular growth factor (antiVEGF) agents have been considered as the gold standard in the treatment… read more here.

Keywords: ranibizumab; bevacizumab; treatment; leavo study ... See more keywords
Photo by kalenemsley from unsplash

Retina: a unique subspecialty in the biosimilar landscape

Sign Up to like & get
recommendations! Published in 2022 at "Eye"

DOI: 10.1038/s41433-022-01984-w

Abstract: Retina as a subspecialty has transformed since the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapeutics more than a decade ago. Approved intravitreal anti-VEGF agents such as ranibizumab (2006) and aflibercept (2011) have made a… read more here.

Keywords: ranibizumab; landscape; retina unique; anti vegf ... See more keywords
Photo from wikipedia

Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab

Sign Up to like & get
recommendations! Published in 2018 at "Ocular Immunology and Inflammation"

DOI: 10.1080/09273948.2016.1247175

Abstract: ABSTRACT Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients… read more here.

Keywords: evanescent white; choroidal neovascularization; multiple evanescent; associated multiple ... See more keywords